Navigation Links
Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
Date:9/1/2010

SAN DIEGO, Sept. 1 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:

  • Robert W. Baird 2010 Health Care Conference on Tuesday, September 14, 2010 at 8:30 a.m. Eastern Time at The St. Regis Hotel in New York City.
  • UBS Global Life Sciences Conference 2010 on Tuesday, September 21, 2010 at 10:00 a.m. Eastern Time at the Grand Hyatt New York in New York City.
  • 5th Annual JMP Securities Healthcare Conference on Monday, September 27, 2010 at 9:00 a.m. Eastern Time at The New York Palace in New York City.

  • (Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

    (Logo:  http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

    Live audio webcasts of these presentations will be accessible on the Company's website at www.optimerpharma.com, under the investors section.  Replays of these presentations will be available at the same location for 30 days after the presentations.

    About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI).  In two Phase 3 trials completed by Optimer to study the safety and efficacy of fidaxomicin for the treatment of CDI, fidaxomicin was statistically superior to vancomycin in global cure rate (defined as cure with no recurre
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2

    Related medicine technology :

    1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
    2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
    3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
    4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
    5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
    6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
    7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
    8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... , Sept. 2, 2015 Research and ... of the "An Introduction to Medical Device ... 2-3, 2015)" conference to their offering. ... introduction to the regulations and requirements that apply ... highly interactive, using real life examples and state-of- ...
    (Date:9/2/2015)... , Sept. 2, 2015 Research and ... the "New EU Pharmacovigilance Legislation (London, UK - ... The 15 new EU modules concerning Pharmacovigilance ... Pharmacovigilance is conducted in Europe . ... these modules and their requirements, examine how they overlap ...
    (Date:9/2/2015)... Sept. 2, 2015  ArmaGen, Inc., a privately ... to treat severe neurological disorders, announced today that ... multi-center Phase 1/2a clinical trial of AGT-181 in ... AGT-181 is an investigational enzyme ... I. The most severe form of MPS I, ...
    Breaking Medicine Technology:An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4
    ... 18 New data evaluating the impact of screening ... prostate cancer screening. The Prostate Conditions Education Council ... a leader in prostate cancer screening, announced today that ... from two studies, including the preliminary data from the ...
    ... Platform Designed for Radial Strength, FlexibilityHOUSTON, March 18 ... in the development and marketing of minimally invasive ... Drug Administration (FDA) has approved an investigational device ... its SUPERA stent, a novel stent platform designed ...
    Cached Medicine Technology:Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data 2Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data 3U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies' SUPERA Peripheral Stent 2
    (Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... Date and ... at Bryn Athyn Church Elementary School, 600 Tomlinson Road, Bryn Athyn, Pa 19009 , ... host a day-long seminar featuring New York Times best-selling author Sam Keen based on ...
    (Date:9/2/2015)... ... September 02, 2015 , ... ... today the launch of its enhanced, cloud-based mobile ePrescribing application. The release of ... on improving prescriber usability. A leader in health technology, RxNT was one of ...
    (Date:9/2/2015)... Waltham, MA (PRWEB) , ... September 02, 2015 ... ... often get swamped with a large stream of mixed documents that include EOBs, ... the various documents, while extracting the data needed to reconcile their billing, with ...
    (Date:9/2/2015)... ... September 02, 2015 , ... Good health and a ... Blue Shield of New Jersey (Horizon BCBSNJ) donated $11,000 to the New Jersey Golf ... the foundation at the start of The Barclays, Horizon BCBSNJ challenged PGA TOUR golfer ...
    (Date:9/2/2015)... ... September 02, 2015 , ... Alameda ... in commemorating “Hunger Action Month” during the entire month of September. In ... will be dedicating its efforts this September to an awareness campaign educating legislators ...
    Breaking Medicine News(10 mins):Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 2Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 4
    ... ... Fax Technology and New HTTPS Platform, , ... Tigard, OR and Salem, OR (PRWEB) September 23, 2009 -- ... FaxBack, a leading provider of reliable VoIP Fax solutions for SMB, enterprise and carrier ...
    ... Oakstone ... the American College of Physicians. Available in two versatile audio formats designed to allow physicians ... ... the first section of the MKSAP 15 Audio Companion . Available in compact disc ...
    ... ... medical device testing , ... OH (PRWEB) September 23, 2009 -- NAMSA,s Analytical Chemistry department is on the move. ... facility is now in use at NAMSA. , , , , ,The ...
    ... with negative sputum tests by a new method, according ... cause of death worldwide, and while the diagnosis of ... can be identified on sputum microscopy, in about half ... making another diagnostic option critical in efforts to control ...
    ... NEW YORK, Sept. 22 Preet Bharara, the U.S. Attorney for ... formerly the senior manager of human resources of Hitachi America Ltd. ... months in prison for defrauding the Hitachi America Group Health and ... was imposed by U.S. District Judge Colleen McMahon. Dowd pleaded guilty ...
    ... , The LFA asks people to join them and ... an FDA-approved medication specifically for lupus , , ... Drug Administration (FDA) approved a medication to treat lupus -- when Dwight ... and effective medications, the Lupus Foundation of America, Inc. (LFA) today launched ...
    Cached Medicine News:Health News:Pangea Communications and FaxBack Extend Their Alliance to Streamline Least Cost Routing and Enhance the Reliability of VoIP-Fax 2Health News:Pangea Communications and FaxBack Extend Their Alliance to Streamline Least Cost Routing and Enhance the Reliability of VoIP-Fax 3Health News:Oakstone Produces Self-Assessment Audio Updates to Support the American College of Physicians' MKSAP 15 2Health News:NAMSA Unveils New, Larger State-of-the-Art Analytical Chemistry Facility 2Health News:New test quickly ID's active TB in smear-negative patients 2Health News:Former Corporate Benefits Manager Sentenced to 57 Months in Prison for Defrauding Health Care Plan of More Than $6 Million Dollars 2Health News:The Lupus Foundation of America, Inc. Asks Supporters to Band Together for Lupus(SM) 2
    Intermittent catheter...
    Intermittent catheter...
    Intermittent catheter...
    Disease diagnosis and treatment reference sourced from Griffith's 5-Minute Clinical Consult. Save time diagnosing and treating more than 1,200 diseases and conditions....
    Medicine Products: